AbbVie, Inc. (ABBV)

In the past six months, AbbVie's stock has risen by 8.0%, driven by the successful launch of Skyrizi and Rinvoq. Skyrizi and Rinvoq generated combined sales of $5.1 billion in the first quarter of 2025, reflecting over 65% growth. The company expects combined sales of these two drugs to reach around $24.7 billion in 2025 and more than $31 billion by 2027. AbbVie reported revenues of $13.34 billion in Q1 2025, an 8.4% year-over-year increase, and raised its full-year adjusted EPS guidance to between $12.09 and $12.29. The European Commission granted marketing authorization for Elahere, and AbbVie announced an exclusive global licensing agreement with Ichnos Glenmark Innovation (IGI) for ISB 2001. AbbVie also announced its intent to acquire Capstan Therapeutics, and the FDA accepted for review Allergan Aesthetics' Premarket Approval Application for SKINVIVE by JUVÉDERM® for the improvement of neck appearance. AbbVie increased its quarterly dividend from $1.55 to $1.64 per share in 2024.

AbbVie's business generally does not have significant seasonality, but its product revenues can be influenced by end-customer and retail buying patterns, as well as fluctuations in wholesaler inventory levels. In 2024, three wholesale distributors—McKesson Corporation, Cardinal Health, Inc., and Cencora, Inc.—accounted for substantially all of AbbVie's pharmaceutical product sales in the United States.

AbbVie Inc. is a global biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of advanced therapies for complex and serious diseases, operating within the Healthcare sector. Its product portfolio is diversified across several key therapeutic areas, including immunology, oncology, neuroscience, aesthetics, and eye care. Major products include Humira, Skyrizi, Rinvoq, Imbruvica, Venclexta, Elahere, Epkinly, Vraylar, Botox Therapeutic, Duopa, Duodopa, Ubrelvy, Qulipta, Botox Cosmetic, Juvederm Collection, Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, Mavyret/Maviret, Creon, and Linzess/Constella.

AbbVie has a significant global presence, operating in over 70 countries and marketing its products in over 175 countries. The company has a presence in the US, Canada, Mexico, China, Australia, Spain, France, the European Union, Japan, and Brazil, among other countries. As of December 2024, AbbVie owned 602 facilities globally, including 10 R&D facilities in the US and one each in Japan and Germany. Net sales are geographically distributed, with the United States accounting for 76.4% of sales, followed by Germany (2.6%), Japan (2%), Canada (1.9%), China (1.6%), France (1.4%), Spain (1%), the United Kingdom (0.9%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and other regions (9.7%).

AbbVie has historically been recognized for its reputation within the pharmaceutical industry, including being named the Most Reputable Pharmaceutical Company in 2017. The company has also been recognized as a "FORTUNE 100 Best Company to Work For" and ranked highly on Fortune's "World's Best Workplaces" list. The company's ongoing commitment to research and development, strategic acquisitions, and community engagement contribute to its overall image. AbbVie funded a new public grade school in North Chicago, demonstrating its commitment to local communities, and its focus on addressing complex diseases and its robust pipeline of new drugs also positively contribute to its reputation.

AbbVie Inc. has a diverse ownership structure, with a mix of institutional, retail, and individual investors. As of July 18, 2025, AbbVie Inc. has 5305 institutional owners and shareholders who have filed 13D/G or 13F forms with the SEC, holding a total of 1,494,817,592 shares. Major institutional owners include Vanguard Group Inc, BlackRock, Inc., State Street Corp, JPMorgan Chase & Co, Morgan Stanley, Geode Capital Management, Llc, Capital Research Global Investors and Bank Of America Corp /de/. Institutional ownership accounts for approximately 68.87% of the company's shares, while individuals hold about 0.07%.